North America Igg4 Related Disease Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2021 –2028 |
 Market Size (Base Year) |
USD 1,856.39 Million |
 Market Size (Forecast Year) |
USD 2,490.06 Million |
 CAGR |
% |
| Major Markets Players |
北美 IgG4 相关疾病市场，按疾病类型（1 型（IgG4 相关）自身免疫性胰腺炎 (AIP)、腹膜后纤维化、IgG4 相关小管间质性肾炎 (TIN)、IgG4 相关硬化性胆管炎 IgG4 相关泪腺炎和涎腺炎、IgG4 相关硬脑膜炎、IgG4 相关甲状腺疾病、血清IgG4 浓度等）、类型（诊断和治疗）、给药途径（肠外、口服和其他）、最终用户（医院、专科诊所和其他）分销渠道（医院药房、零售药房、网上药房和其他）、国家（美国、加拿大和墨西哥）行业趋势和预测到 2028 年
市场分析与洞察：北美 IgG4 相关疾病市场
北美 IgG4 相关疾病市场预计将在 2021 年至 2028 年期间实现显着增长。Data Bridge Market Research 分析称，北美 IgG4 相关疾病市场在 2021 年至 2028 年的预测期内以 4.1% 的复合年增长率增长，预计将从 2020 年的 18.5639 亿美元增至 2028 年的 24.9006 亿美元。创新和技术的升级以及先进医疗技术的可用性是预测期内市场增长的主要预期驱动力。
越来越多的人受到 IgG4 相关疾病的影响，这需要高效和先进的治疗来最大限度地降低风险。医疗保健系统在治疗患者期间需要针对多种不同类型的 IgG4 相关疾病的高度先进的药物。因此，主要市场参与者高度关注产品发布和产品批准。此外，政府和监管机构正在支持市场参与者进行产品审批。
北美 IgG4 相关疾病市场技术进步日新月异，这是推动因素。医疗支出的不断增长可以成为市场增长的机会。COVID-19 的出现推迟了疾病的诊断，给市场带来了挑战。预计高昂的治疗费用将在预测期内阻碍市场增长。
北美 IgG4 相关疾病市场报告提供了市场份额、新发展和产品线分析的详细信息，国内和本地市场参与者的影响，分析了新兴收入领域、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况，请联系我们获取分析师简报；我们的团队将帮助您创建收入影响解决方案，以实现您的预期目标。
北美 IgG4 相关疾病市场范围和市场规模
北美 IgG4 相关疾病市场根据疾病类型、类型、给药途径、最终用户和分销渠道进行细分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
- 根据疾病类型，北美 IgG4 相关疾病市场细分为 1 型（IgG4 相关）自身免疫性胰腺炎 (AIP)、腹膜后纤维化、IgG4 相关小管间质性肾炎 (TIN)、IgG4 相关硬化性胆管炎、IgG4 相关泪腺炎和唾液腺炎、IgG4 相关硬脑膜炎、IgG4 相关甲状腺疾病、血清 IgG4 浓度等。2021 年，由于 FDA 批准了新的生物仿制药，IgG4 相关泪腺炎和唾液腺炎细分市场预计将占据市场主导地位。
- 根据类型，北美 IgG4 相关疾病市场分为诊断和治疗。2021 年，由于 IgG4 相关疾病病例激增，诊断领域预计将占据市场主导地位。
- 根据给药途径，北美 IgG4 相关疾病市场分为口服、肠外和其他。2021 年，肠外给药预计将占据市场主导地位，因为它是最有效的给药方式，患者依从性更好。
- 根据最终用户，北美 IgG4 相关疾病市场分为医院、专科诊所和其他。由于医疗支出不断增加，预计 2021 年医院部门将占据市场主导地位。
- 根据分销渠道，北美 IgG4 相关疾病市场细分为医院药房、零售药房、在线药房和其他。2021 年，由于研发活动的增加，预计医院药房部门将占据市场主导地位。
北美 IgG4 相关疾病市场国家级分析
分析了北美 IgG4 相关疾病市场，并根据疾病类型、类型、给药途径、最终用户和分销渠道提供了市场规模信息。北美 IgG4 相关疾病市场报告涵盖的国家包括美国、加拿大、墨西哥。
由于该地区技术进步不断提高，北美有望主导北美 IgG4 相关疾病市场。由于人们对 IgG4 相关疾病的认识不断提高，美国在市场中占据主导地位，并引领北美 IgG4 相关疾病市场的增长。
新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是预测各个国家市场情况的一些主要指标。此外，在对国家数据进行预测分析时，还会考虑北美品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、销售渠道的影响。
北美 igG4 相关疾病市场医疗支出的不断增长以及创新技术的不断升级为参与者创造了新的机遇
美国 IgG4 相关疾病类型细分市场预计将以最高速度增长，并且由于创新和技术的不断发展，它将在 2021 年至 2028 年的预测期内主导北美地区。
北美 IgG4 相关疾病市场还为您提供每个国家/地区特定行业增长的详细市场分析，包括市场销售、市场发展的影响以及监管情景的变化及其对北美 IgG4 相关疾病市场的支持。数据涵盖 2010 年至 2019 年的历史时期。
竞争格局和北美 IgG4 相关疾病市场份额分析
北美 IgG4 相关疾病市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用主导地位和技术生命线曲线。以上数据点仅与公司对北美 IgG4 相关疾病市场的关注有关。
报告中涉及的主要参与者包括 Hikma Pharmaceuticals PLC、Zydus Cadila、Lannett、Sun Pharmaceutical Industries Ltd、Baxter、Viatris Inc.、Amgen Inc.、Sandoz International GmbH（Novartis AG 的子公司）、Fresenius Kabi USA（Fresenius SE & Co. KGaA 的子公司）、Pfizer Inc.、Cipla Inc.、Celltrion Healthcare Co., Ltd.、Antares Pharma、Amneal Pharmaceuticals LLC、Accord-UK Ltd.、Genentech, Inc.、Ingenus Pharmaceuticals、STI PHARMA、SEBELA PHARMACEUTICAL、ANI Pharmaceuticals, Inc. 以及其他国内和北美参与者。DBMR 分析师了解竞争优势并为每个竞争对手分别提供竞争分析。
全球各地的公司也发起了许多产品发布和协议，进一步加速了北美 IgG4 相关疾病市场的发展。
例如，
- 2021 年 3 月，STI Pharma 宣布推出功能和设计更佳的新网站。这增加了客户群以及产品在市场上的销量和需求
- 2021 年 8 月，MediPrint™ Ophthalmics 宣布了新的企业品牌和新网站。新网站展示了企业及其团队的创新制药愿景和视力保护使命。它提供了有关 MediPrint Ophthalmics 如何最初开发一种高度创新的解决方案来满足青光眼领域尚未满足的重大需求的信息。这增加了产品的销售和需求，并有助于创收
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA IGG4-RELATED DISEASE MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER'S 5 FORCES
5 REGIONAL SUMMARY
5.1 SUMMARY WRITE UP (NORTH AMERICA)
5.1.1 OVERVIEW
5.2 SUMMARY WRITE UP (EUROPE)
5.2.1 OVERVIEW
5.3 SUMMARY WRITE UP (ASIA-PACIFIC)
5.3.1 OVERVIEW
5.4 SUMMARY WRITE UP (SOUTH AMERICA)
5.4.1 OVERVIEW
5.5 SUMMARY WRITE UP (MIDDLE EAST AND AFRICA)
5.5.1 OVERVIEW
6 EPIDEMIOLOGY
7 REGULATORY GUIDELINES FOR NORTH AMERICA IGG4-RELATED DISEASE MARKET
7.1 U.S. REGULATORY FRAMEWORK
7.2 EUROPE REGULATORY FRAMEWORK
7.3 JAPAN REGULATORY FRAMEWORK
8 PIPELINE ANALYSIS
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISING AWARENESS ABOUT IMMUNOGLOBULIN G4-RELATED DISEASE (IGG4-RD)
9.1.2 ESCALATION IN INNOVATION AND TECHNOLOGIES
9.1.3 INCREASE IN RESEARCH & DEVELOPMENT INVESTMENT FOR DRUG DISCOVERY
9.2 RESTRAINTS
9.2.1 HIGH COST OF IMMUNOGLOBULIN G4-RELATED DISEASE (IGG4-RD) TREATMENT
9.2.2 ADVERSE EFFECTS ASSOCIATED WITH TREATMENT
9.3 OPPORTUNITIES
9.3.1 RISING EXPENDITURE ON HEALTHCARE
9.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
9.3.3 GOVERNMENT FUNDING FOR RESEARCH PURPOSE
9.4 CHALLENGE
9.4.1 DIFFICULT DIAGNOSIS AND MANGEMENT OF THE DISEASE
10 IMPACT OF COVID 19 PANDEMIC ON THE MARKET
10.1 PRICE IMPACT
10.2 IMPACT ON SUPPLY CHAIN
10.3 IMPACT ON DEMAND
10.4 STRATEGIC DECISIONS FOR MANUFACTURERS
10.5 CONCLUSION
11 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE
11.1 OVERVIEW
11.2 IGG4-RELATED DACRYOADENITIS AND SIALADENITIS
11.3 RETROPERITONEAL FIBROSIS
11.4 IGG4-RELATED THYROID DISEASE
11.5 IGG4-RELATED TUBULOINTERSTITIAL NEPHRITIS (TIN)
11.6 IGG4-RELATED SCLEROSING CHOLANGITIS
11.7 TYPE 1 (IGG4-RELATED) AUTOIMMUNE PANCREATITIS (AIP)
11.8 IGG4-RELATED PACHYMENINGITIS
11.9 OTHERS
12 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY TYPE
12.1 OVERVIEW
12.2 DIAGNOSTIC
12.2.1 IMAGING
12.2.1.1 COMPUTED TOMOGRAPHY (CT)
12.2.1.2 MAGNETIC RESONANCE IMAGING (MRI)
12.2.1.3 PET/CT
12.2.1.4 OTHERS
12.2.2 LABORATORY TESTING (SERUM IGG4 CONCENTRATION)
12.2.3 FLOW CYTOMETRY
12.2.4 OTHERS
12.3 TREATMENT
12.3.1 RITUXIMAB
12.3.2 CYCLOPHOSPHAMIDE
12.3.3 METHOTREXATE
12.3.4 STEROIDS
12.3.4.1 Methylprednisolone
12.3.4.2 Prednisolone
12.3.4.3 others
12.3.5 AZATHIOPRINE
12.3.6 OTHERS
13 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 PARENTERAL
13.3 ORAL
13.4 OTHERS
14 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CLINICS
14.4 OTHERS
15 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 HOSPITAL PHARMACY
15.3 RETAIL PHARMACY
15.4 ONLINE PHARMACY
15.5 OTHERS
16 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY REGION
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA IGG4-RELATED DISEASE MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 PFIZER INC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 AMGEN INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 GENENTECH, INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 COMPANY SHARE ANALYSIS
19.3.3 PRODUCT PORTFOLIO
19.3.4 RECENT DEVELOPMENT
19.4 CELLTRION HEALTHCARE CO., LTD.
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENT
19.5 SANDOZ INTERNATIONAL GMBH (A SUBSIDIARY OF NOVARTIS AG)
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.6 ACCORD-UK LTD.
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 AMNEAL PHARMACEUTICALS LLC
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 ANI PHARMACEUTICALS, INC.
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENT
19.9 ANTARES PHARMA
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.1 BAXTER
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 CIPLA INC.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS SE & CO. KGAA)
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 HIKMA PHARMACEUTICALS PLC
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 INGENUS PHARMACEUTICALS
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 LANNETT
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENTS
19.16 SEBELA PHARMACEUTICALS
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 STI PHARMA
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENT
19.18 SUN PHARMACEUTICAL INDUSTRIES LTD.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 VIATRIS INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENT
19.2 ZYDUS CADILA
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENT
20 COMPANIES WITH PRODUCTS IN PHASE II AND PHASE III CLINICAL TRIALS
20.1 SANOFI
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 PRODUCT PORTFOLIO
20.1.4 RECENT DEVELOPMENT
20.2 XENCOR
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 PRODUCT PORTFOLIO
20.2.4 RECENT DEVELOPMENT
20.3 BRISTOL-MYERS SQUIBB COMPANY
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT DEVELOPMENTS
20.4 HORIZON THERAPEUTICS PLC
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA IGG4-RELATED DISEASE MARKET, PIPELINE ANALYSIS
TABLE 2 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 3 NORTH AMERICA IGG4-RELATED DACRYOADENITIS AND SIALADENITIS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 4 NORTH AMERICA RETROPERITONEAL FIBROSIS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 5 NORTH AMERICA IGG4-RELATED THYROID DISEASE IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 6 NORTH AMERICA IGG4-RELATED TUBULOINTERSTITIAL NEPHRITIS (TIN) IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 7 NORTH AMERICA IGG4-RELATED SCLEROSING CHOLANGITIS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 8 NORTH AMERICA TYPE 1 (IGG4-RELATED) AUTOIMMUNE PANCREATITIS (AIP) IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 9 NORTH AMERICA IGG4-RELATED PACHYMENINGITIS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 10 NORTH AMERICA OTHERS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 11 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 12 NORTH AMERICA DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 13 NORTH AMERICA DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 14 NORTH AMERICA IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 15 NORTH AMERICA TREATMENT IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 16 NORTH AMERICA TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 17 NORTH AMERICA STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 18 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 19 NORTH AMERICA PARENTERAL IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 20 NORTH AMERICA ORAL IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 21 NORTH AMERICA OTHERS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 22 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY END USERS, 2019-2028 (USD THOUSAND)
TABLE 23 NORTH AMERICA HOSPITALS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 24 NORTH AMERICA SPECIALTY CLINICS IN NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 25 NORTH AMERICA OTHERS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 26 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 27 NORTH AMERICA HOSPITAL PHARMACY IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 28 NORTH AMERICA RETAIL PHARMACY IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 29 NORTH AMERICA ONLINE PHARMACY IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 30 NORTH AMERICA OTHERS IN IGG4-RELATED DISEASE MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 31 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY COUNTRY, 2019-2028 (USD THOUSAND)
TABLE 32 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 33 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 34 NORTH AMERICA DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 35 NORTH AMERICA IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 36 NORTH AMERICA TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 37 NORTH AMERICA STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 38 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 39 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 40 NORTH AMERICA IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 41 U.S. IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 42 U.S. IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 43 U.S. DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 44 U.S. IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 45 U.S. TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 46 U.S. STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 47 U.S. IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 48 U.S. IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 49 U.S. IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 50 CANADA IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 51 CANADA IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 52 CANADA DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 53 CANADA IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 54 CANADA TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 55 CANADA STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 56 CANADA IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 57 CANADA IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 58 CANADA IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
TABLE 59 MEXICO IGG4-RELATED DISEASE MARKET, BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
TABLE 60 MEXICO IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 61 MEXICO DIAGNOSTIC IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 62 MEXICO IMAGING IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 63 MEXICO TREATMENT IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 64 MEXICO STEROIDS IN IGG4-RELATED DISEASE MARKET, BY TYPE, 2019-2028 (USD THOUSAND)
TABLE 65 MEXICO IGG4-RELATED DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
TABLE 66 MEXICO IGG4-RELATED DISEASE MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 67 MEXICO IGG4-RELATED DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
图片列表
FIGURE 1 NORTH AMERICA IGG4-RELATED DISEASE MARKET : SEGMENTATION
FIGURE 2 NORTH AMERICA IGG4-RELATED DISEASE MARKET : DATA TRIANGULATION
FIGURE 3 NORTH AMERICA IGG4-RELATED DISEASE MARKET : DROC ANALYSIS
FIGURE 4 NORTH AMERICA IGG4-RELATED DISEASE MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA IGG4-RELATED DISEASE MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA IGG4-RELATED DISEASE MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA IGG4-RELATED DISEASE MARKET : DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA IGG4-RELATED DISEASE MARKET : MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA IGG4-RELATED DISEASE MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA IGG4-RELATED DISEASE MARKET : SEGMENTATION
FIGURE 11 INCREASING AWARENESS FOR IGG4-RELATED DISEASES AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE NORTH AMERICA IGG4-RELATED DISEASE MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 IGG4-RELATED DACRYOADENITIS AND SIALADENITIS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA IGG4-RELATED DISEASE MARKET IN 2021 & 2028
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: NORTH AMERICA IGG4-RELATED DISEASE MARKET
FIGURE 14 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE, 2020
FIGURE 15 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE, 2019-2028 (USD THOUSAND)
FIGURE 16 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE, CAGR (2021-2028)
FIGURE 17 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY TYPE, 2020
FIGURE 19 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY TYPE, 2019-2028 (USD THOUSAND)
FIGURE 20 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 21 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 23 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD THOUSAND)
FIGURE 24 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 25 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 26 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY END USERS, 2020
FIGURE 27 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY END USERS, 2019-2028 (USD THOUSAND)
FIGURE 28 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY END USERS, CAGR (2021-2028)
FIGURE 29 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY END USERS, LIFELINE CURVE
FIGURE 30 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 31 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD THOUSAND)
FIGURE 32 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY DISTRIBUTION CHANNEL,CAGR (2021-2028)
FIGURE 33 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 NORTH AMERICA IGG4-RELATED DISEASE MARKET: SNAPSHOT (2020)
FIGURE 35 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY COUNTRY (2020)
FIGURE 36 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY COUNTRY (2021 & 2028)
FIGURE 37 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY COUNTRY (2020 & 2028)
FIGURE 38 NORTH AMERICA IGG4-RELATED DISEASE MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 39 NORTH AMERICA IGG4-RELATED DISEASEMARKET: COMPANY SHARE 2020 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
